Since this breakthrough, several immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1), have been widely used for various tumors due to their sustained anti-tumor response and significant efficacy. Here, PDCD1 is linked to neoplasm.